Hematopoietic cellular therapy: Implications for the flow cytometry laboratory

Hematology/Oncology Clinics of North America

Volumn 16, Issue 2, 2002, Pages 455-476

  Lamb Jr , Lawrence S ^a  

^a South Carolina Cancer Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

T LYMPHOCYTE RECEPTOR; CD34 ANTIGEN; FLUORESCENT DYE;

ADOPTIVE IMMUNOTHERAPY; B LYMPHOCYTE; BONE MARROW TRANSPLANTATION; FLOW CYTOMETRY; GRAFT FAILURE; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HEMATOPOIETIC STEM CELL; HEMATOPOIETIC SYSTEM; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; LABORATORY; MAJOR HISTOCOMPATIBILITY COMPLEX; NATURAL KILLER CELL; PRIORITY JOURNAL; RELAPSE; REVIEW; T LYMPHOCYTE; ANIMAL; BLOOD; CELL COUNT; CELL SEPARATION; CHEMISTRY; CLASSIFICATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY; IMMUNOLOGY; LYMPHOCYTE DEPLETION; METHODOLOGY; T LYMPHOCYTE SUBPOPULATION;

ANIMALS; ANTIGENS, CD34; CELL COUNT; CELL SEPARATION; FLOW CYTOMETRY; FLUORESCENT DYES; GRAFT REJECTION; GRAFT VS HOST DISEASE; GRAFT VS LEUKEMIA EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOPHENOTYPING; LYMPHOCYTE DEPLETION; T-LYMPHOCYTE SUBSETS; TRANSPLANTATION CHIMERA;

EID: 0035991380     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8588(01)00014-4     Document Type: Article

References (96)

1. Quantification of CD34+ cells mobilized into the peripheral blood predicts the yield of the leukopheresis product and can replace progenitor assays
2. Antigenic analysis of hematopoiesis III: A hematopoietic progenitor cell surface antigen defined by a monoclonal antibody raised against KG-1a cells
3. Engraftment after infusion of CD34+ marrow cells in patients with breast cancer or neuroblastoma
4. Clinical utility in maximizing CD34+ cell count in stem cell grafts
5. Factors predicting engraftment of autologous blood stem cells: CD34+ subsets inferior to total cell dose
6. Flow cytometry for clinical estimation of circulating hematopoietic progenitors for autologous transplantation in cancer patients
7. Measurement of CD34+ cells in bone marrow by flow cytometry
8. The ISHAGE guidelines for CD34+ cell determination by flow cytometry
9. The influence of flow cytometry gating strategy on the standardization of CD34+ cell quantitation: An Australian multicenter study
10. CD34+ cell enumeration in the peripheral blood and apheresis samples, using two laboratory diagnostic kits or an institutional protocol
11. Determination of CD34 absolute count from apheresis specimens shipped overnight to a single reference laboratory: A comparison of single and dual platform methods
12. Effects of in vitro depletion of T cells in HLA identical allogeneic marrow grafts
13. Evidence for the involvement of host-derived OKT8 positive T cells in the rejection of T depleted HLA-identical bone marrow grafts
14. Graft versus leukemia reactions after bone marrow transplantation
15. Graft failure following transplantation of T cell depleted marrow in graft versus host disease
16. Graft failure in patients receiving T-cell-depleted HLA identical allogeneic marrow transplants
17. Graft rejection in recipients of T cell-depleted HLA-nonidentical marrow transplants for leukemia
18. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase: Increased risk for relapse associated with T-cell depletion
19. The role of donor lymphoid cells in allogeneic marrow engraftment
20. Glucocorticoid-mediated repression of nuclear factor-kappa-B-dependent transcription involves direct interference with transactivation
21. Characterization of acute bone marrow graft rejection in T cell-depleted, partially mismatched related donor bone marrow transplantation
22. Graft failure after bone marrow transplantation from unrelated donors using busulfan and cyclophosphamide for conditioning
23. Characterization of cells emerging at the time of graft failure after bone marrow transplantation from an unrelated marrow donor
24. Acute rejection of marrow grafts in patients transplanted from a partially mismatched related donor: Clinical and immunologic characteristics
25. Donor leukocyte infusion for treatment of graft rejection post partially mismatched related donor bone marrow transplant
26. Effect of HLA compatibility on engraftment of bone marrow transplants in patients with leukemia or lymphoma
27. Effect of HLA incompatibility on graft-versus-host disease, relapse and survival after marrow transplantation for patients with leukemia or lymphoma
28. Allogeneic marrow transplants: Approaches for the patient lacking a donor
29. Immunophenotyping of peripheral blood lymphocytes in the diagnosis of acute graft-versus-host disease
30. Reconstitution of T-cell function after CD6-depleted allogeneic bone marrow transplantation
31. Phenotypic and functional reconstitution of peripheral blood lymphocytes following T cell-depleted bone marrow transplantation from partially mismatched related donors
32. Selective depletion of myelin-reactive T cells with the OX-40 antibody ameliorates autoimmune encephalomyelitis
33. Expression of the T-cell activation antigen, OX-40, identifies alloreactive T cells in acute graft-versus-host disease
34. Identification of a human OX-40 ligand, a costimulator of CD4+ T cells with homology to tumor necrosis factor
35. OX-40 ligand: A potent costimulatory molecule for sustaining primary CD4 T cell responses
36. Expression of CD134 (OX-40) on T cells during the first 100 days following allogeneic bone marrow transplantation as a marker for lymphocyte activation and therapy-resistant graft-versus-host disease
37. Marrow transplantation from related donors other than HLA-identical siblings
38. T cell depletion of human bone marrow: Comparison of Campath I plus complement, anti-T cell a-chain immunotoxin, and soybean agglutinin alone or in combination with sheep erythrocytes or immunomagnetic beads
39. Graft failure after T cell depleted human leukocyte antigen identical marrow transplants for leukemia
40. In vitro generation of allospecific human CD8+ T cells of Tc1 and Tc2 phenotype
41. Graft-versus-host disease in bone marrow transplantation: Experimental, laboratory, and clinical contributions of the last few years
42. Graft-versus-host disease
43. Frequency of bone marrow T cells responding to HLA-identical non-leukemic and leukemic stimulator cells
44. Bone marrow transplantation from related donors other than HLA-identical siblings: Effect of T cell depletion
45. Combined in vitro and in vivo T lymphocyte depletion for the control of graft-versus-host disease following haploidentical marrow transplant
46. Comparison of OKT-3 and T10B9 for ex vivo T cell depletion of partially mismatched related donor bone marrow transplantation
47. Use of partially mismatched related donors extends access to allogeneic marrow transplant
48. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype
49. Use of unrelated marrow grafts compensates for reduced graft-versus-leukemia reactivity after T cell depleted allogeneic marrow transplantation for chronic myelogenous leukemia
50. Allogeneic cell therapy for relapsed leukemia after bone marrow transplantation with donor peripheral blood lymphocytes
51. Graft-versus-leukemia: No longer an epiphenomenon
52. Strategies to enhance the graft-versus-malignancy effect in allogeneic transplants
53. Principles of graft-versus-leukemia reactivity
54. T cell depletion of HLA and haploidentical marrow reduces graft-versus-host disease but it may impair a graft-versus-leukemia effect
55. Interleukin 2 prevents graft-versus-host disease while preserving the graft-versus-leukemia effect of allogeneic T cells
56. Separation of graft-versus-host disease and graft-versus-leukemia effect against chronic myelogenous leukemia
57. Gamma/delta T cell clones and natural killer cell clones mediate distinct patterns of non-major histocompatibility-restricted cytolysis
58. Human peripheral gamma/delta T cells recognize hsp60 molecules on Daudi Burkitt's lymphoma cells
59. Gamma delta T cell receptor analysis supports a role for HSP 70 selection of lymphocytes in multiple sclerosis lesions
60. Potential antileukemic effect of gamma delta T cells in acute lymphoblastic leukemia
61. Phenotypic analysis of Ag-specific T lymphocytes
62. Counting Ag-specific CD8 T cells: A reevaluation of bystander activation during viral infection
63. Characterization of circulating T cells specific for tumor-associated Ags in melanoma patients
64. High frequency of skin-homing melanocyte-specific cytotoxic T lymphocytes in autoimmune vitiligo
65. Cutting edge: Rapid cloning of tumor-specific CTL suitable for adoptive immunotherapy of melanoma
66. Recombinant human single-chain MHC-peptide complexes made from E. coli by in vitro refolding: Functional single-chain MHC-peptide complexes and tetramers with tumor associated Ags
67. Critical role for CD8 in binding of MHC tetramers to TCR: CD8 antibodies block specific binding of human tumor-specific MHC-peptide tetramers to TCR
68. Cutting edge: Characterization of allorestricted and peptide-selective alloreactive T cells using HLA-tetramer selection
69. Direct detection and magnetic isolation of Chlamydia trachomatis major outer membrane protein-specific CD8+ CTLs with HLA Class I tetramers
70. Isolation and expansion of cytomegalovirus-specific cytotoxic T lymphocytes to clinical scale from a single blood draw using dendritic cells and HLA-tetramers
71. Allo-major histocompatibility complex-restricted cytotoxic T lymphocytes engraft in bone marrow transplant recipients without causing graft-versus-host-disease
72. Non-MHC-restricted cytotoxic cells: Their roles in the control and treatment of leukaemias
73. Infection complicating bone marrow transplantation
74. Reconstruction of the hematopoietic and immune systems after marrow transplantation
75. The kinetics of immune reconstitution after human bone marrow transplantation
76. Immunoreconstitution after human bone marrow transplantation
77. Immune reconstitution following bone marrow transplantation: Comparison of recipients of T cell depleted marrow with recipients of conventional marrow grafts
78. Comparison of immune reconstitution after unrelated and related T cell depleted bone marrow transplantation: Effect of patient age and donor leukocyte infusions
79. Prolonged CD4 depletion after sequential autologous peripheral blood progenitor cell infusions in children and young adults
80. T-cell regeneration: All repertoires are not created equal
81. Age, thymopoiesis, and CD4+ T-lymphocyte regeneration after intensive chemotherapy
82. Distinctions between CD8+ and CD4+ T-cell regenerative pathways result in prolonged T-cell subset imbalance after intensive chemotherapy
83. Reconstruction of the immune system after unrelated or partially matched T-cell-depleted bone marrow transplantation in children: Immunophenotypic analysis and factors affecting the speed of recovery
84. T-lymphocyte reconstitution in recipients of bone marrow transplants with and without GvHD: Imbalances of T-cell subpopulations having unique regulatory and cognitive functions
85. Immune reconstitution following allogeneic peripheral blood progenitor cell transplantation: Comparison of recipients of positive CD34+ selected grafts with recipients of unmanipulated grafts
86. Rapid flow cytometric method for measuring lymphocyte subset activation
87. Measurement of T cell CD69 expression: A rapid and efficient means to assess mitogen-or antigen-induced proliferative capacity in normals
88. A whole-blood assay for qualitative and semiquantitative measurements of CD69 surface expression on CD4 and CD8 T lymphocytes using flow cytometry
89. Reconstitution of B cell immunity following bone marrow transplantation
90. B-cell differentiation following autologous, conventional, or T-cell depleted bone marrow transplantation: A recapitulation of normal B-cell ontogeny
91. Abundance of a restricted fetal B cell repertoire in marrow transplant recipients
92. Long lasting IgG subclass and antibacterial polysaccharide antibody deficiency after allogeneic bone marrow transplantation
93. Recovery of antibody production in human allogeneic marrow graft recipients: Influence of time post transplantation, the presence or absence of chronic graft-versus-host-disease, and antithymocyte globulin treatment
94. The effect of thymic function on immunocompetence following bone marrow transplantation
95. Determination of natural killer cell function by flow cytometry
96. A flow cytometric long-term cytotoxicity assay